PMADS

Id:	acc1663
Group:	2sens
Protein:	endoglin
Gene Symbol:	ENG
Protein Id:	P17813
Protein Name:	EGLN_HUMAN
PTM:	phosphorylation
Site:	Thr
Site Sequence:
Disease Category:	Cancer
Disease:	Prostate Cancer
Disease Subtype:
Disease Cellline:	PC3-M
Disease Info:
Drug:	TGF-beta1
Drug Info:	-
Effect:	modulate
Effect Info:	Endoglin regulates cell migration in prostate cancer PC3 - M cells through the phosphorylation of ALK2 and ALK5 receptors.
Note:
Score:	4.0
Pubmed(PMID):	19736306
Sentence Index:	19736306_3-4
Sentence:	"The current study indicates that endoglin is phosphorylated on cytosolic domain threonine residues by the TGF-beta type I receptors ALK2 and ALK5 in prostate cancer cells. Importantly, in the presence of constitutively active ALK2, endoglin did not inhibit cell migration, suggesting that endoglin phosphorylation regulated PC3-M cell migration."

Sequence & Structure:

MDRGTLPLAVALLLASCSLSPTSLAETVHCDLQPVGPERGEVTYTTSQVSKGCVAQAPNAILEVHVLFLEFPTGPSQLELTLQASKQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVNTTELPSFPKTQILEWAAERGPITSAAELNDPQSILLRLGQAQGSLSFCMLEASQDMGRTLEWRPRTPALVRGCHLEGVAGHKEAHILRVLPGHSAGPRTVTVKVELSCAPGDLDAVLILQGPPYVSWLIDANHNMQIWTTGEYSFKIFPEKNIRGFKLPDTPQGLLGEARMLNASIVASFVELPLASIVSLHASSCGGRLQTSPAPIQTTPPKDTCSPELLMSLIQTKCADDAMTLVLKKELVAHLKCTITGLTFWDPSCEAEDRGDKFVLRSAYSSCGMQVSASMISNEAVVNILSSSSPQRKKVHCLNMDSLSFQLGLYLSPHFLQASNTIEPGQQSFVQVRVSPSVSEFLLQLDSCHLDLGPEGGTVELIQGRAAKGNCVSLLSPSPEGDPRFSFLLHFYTVPIPKTGTLSCTVALRPKTGSQDQEVHRTVFMRLNIISPDLSGCTSKGLVLPAVLGITFGAFLIGALLTAALWYIYSHTRSPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target	Drug name	MOA	Phase	Status	Disease	Source
ENG	CAROTUXIMAB	Endoglin inhibitor	3	Completed	angiosarcoma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	2	Completed	hepatocellular carcinoma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	2	Completed	clear cell renal carcinoma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	2	Completed	glioblastoma multiforme	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	2	Terminated	glioblastoma multiforme	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	2	Completed	papillary renal cell carcinoma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	2	Completed	age-related macular degeneration	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	2	Completed	choriocarcinoma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	2	Terminated	placental site trophoblastic tumor	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	2	Completed	prostate cancer	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	2	Recruiting	prostate cancer	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	2	Terminated	gestational trophoblastic neoplasm	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Completed	hepatocellular carcinoma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Completed	neoplasm	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Terminated	renal cell carcinoma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Completed	age-related macular degeneration	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Completed	anaplastic astrocytoma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Completed	anaplastic oligodendroglioma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Completed	non-small cell lung carcinoma	ClinicalTrials ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Recruiting	non-small cell lung carcinoma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Completed	metastasis	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Completed	gliosarcoma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Completed	soft tissue sarcoma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Completed	mixed glioma	ClinicalTrials
ENG	CAROTUXIMAB	Endoglin inhibitor	1	Completed	cancer	ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

ENGASE-Ser49
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-1.528
GBM	-0.252
HNSC
LUAD	0.252
LUSC
non_ccRCC	0.333
PDAC
UCEC	1.195

ENGASE-Ser64
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.24
GBM	-0.698
HNSC
LUAD	-0.535
LUSC
non_ccRCC
PDAC
UCEC	1.473

ENGASE-Ser66
Cancer	Intensity
BRCA
COAD	-0.145
HGSC
ccRCC	-0.201
GBM	1.231
HNSC
LUAD	-1.45
LUSC
non_ccRCC
PDAC
UCEC	0.566

LENG1-Ser59
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

LENG8-Ser336
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM
HNSC
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

LENG8-Ser351
Cancer	Intensity
BRCA	-1.579
COAD	-0.167
HGSC	-0.713
ccRCC	0.266
GBM	-0.108
HNSC	0.074
LUAD	0.41
LUSC	-1.029
non_ccRCC	2.27
PDAC	0.699
UCEC	-0.123

LENG8-Thr344
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	1.143
GBM
HNSC	-0.433
LUAD	-0.711
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb